Related Experiment Video
Updated: May 6, 2026
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration
Carlos Eduardo dos Reis Veloso1, Luciana Negrão Frota de Almeida, Franco Maria Recchia
1Department of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Background/Aims:
To investigate the association between VEGF gene polymorphism and response to ranibizumab in neovascular age-related macular degeneration (AMD).
Methods:
A total of 92 patients were genotyped for the VEGF rs1413711 single nucleotide polymorphism. Patients with neovascular AMD initially received 3 monthly ranibizumab intravitreal injections and were retreated as needed. Visual acuity (VA) and central retinal thickness (CRT) were measured before and 1, 3, 6 and 12 months after treatment.
Results:
For patients with TT and CT genotypes, paired comparisons of mean VA showed improvement when the data obtained at all visits were compared with baseline values, in contrast to patients with the CC genotype. CRT statistically improved at all visits for all genotypes.
Conclusion:
Patients with the CC genotype showed poorer long-term functional and anatomical response to anti-VEGF therapy.
Related Concept Videos
01:27Diabetic Retinopathy
01:24Regulation of Angiogenesis and Blood Supply